Leuthold Group’s Elevance Health ELV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-22,531
Closed -$7.9M 216
2025
Q4
$7.9M Buy
+22,531
New +$7.61M 0.85% 37
2024
Q4
Sell
-12,700
Closed -$6.6M 201
2024
Q3
$6.6M Sell
12,700
-846
-6% -$452K 0.73% 50
2024
Q2
$7.34M Sell
13,546
-1,572
-10% -$831K 0.85% 38
2024
Q1
$7.84M Sell
15,118
-87
-0.6% -$43.3K 0.88% 35
2023
Q4
$7.17M Buy
15,205
+231
+2% +$107K 0.9% 36
2023
Q3
$6.52M Buy
14,974
+4,344
+41% +$1.97M 0.91% 27
2023
Q2
$4.72M Sell
10,630
-1,598
-13% -$737K 0.61% 61
2023
Q1
$5.62M Sell
12,228
-8,057
-40% -$3.83M 0.74% 44
2022
Q4
$10.4M Sell
20,285
-467
-2% -$237K 1.4% 11
2022
Q3
$9.43M Sell
20,752
-163
-0.8% -$78K 1.42% 11
2022
Q2
$10.1M Sell
20,915
-547
-3% -$271K 1.43% 13
2022
Q1
$10.5M Buy
21,462
+1,168
+6% +$534K 1.35% 15
2021
Q4
$9.41M Buy
20,294
+9,017
+80% +$3.79M 1.1% 24
2021
Q3
$4.2M Sell
11,277
-1,884
-14% -$716K 0.52% 75
2021
Q2
$5.03M Sell
13,161
-252
-2% -$96.3K 0.62% 59
2021
Q1
$4.82M Sell
13,413
-1,138
-8% -$366K 0.61% 62
2020
Q4
$4.67M Sell
14,551
-861
-6% -$264K 0.62% 61
2020
Q3
$4.14M Sell
15,412
-322
-2% -$86.6K 0.57% 60
2020
Q2
$4.14M Sell
15,734
-370
-2% -$98.7K 0.62% 61
2020
Q1
$3.66M Buy
16,104
+1,296
+9% +$353K 0.66% 56
2019
Q4
$4.47M Sell
14,808
-577
-4% -$159K 0.58% 73
2019
Q3
$3.69M Sell
15,385
-3,476
-18% -$952K 0.48% 86
2019
Q2
$5.32M Sell
18,861
-22,256
-54% -$6.08M 0.69% 53
2019
Q1
$11.8M Sell
41,117
-1,471
-3% -$425K 1.59% 8
2018
Q4
$11.2M Sell
42,588
-4,933
-10% -$1.36M 1.6% 11
2018
Q3
$13M Buy
47,521
+36
+0.1% +$9.35K 1.42% 14
2018
Q2
$11.3M Buy
47,485
+3,240
+7% +$750K 1.24% 17
2018
Q1
$9.72M Sell
44,245
-13,516
-23% -$3.18M 1.11% 16
2017
Q4
$13M Buy
57,761
+6,718
+13% +$1.43M 1.3% 13
2017
Q3
$9.69M Buy
51,043
+5,608
+12% +$1.07M 0.98% 21
2017
Q2
$8.55M Sell
45,435
-752
-2% -$135K 0.92% 24
2017
Q1
$7.64M Sell
46,187
-1,027
-2% -$163K 0.82% 29
2016
Q4
$6.79M Sell
47,214
-4,359
-8% -$584K 0.76% 36
2016
Q3
$6.46M Sell
51,573
-1,510
-3% -$195K 0.68% 54
2016
Q2
$6.97M Buy
53,083
+6,048
+13% +$828K 0.74% 44
2016
Q1
$6.54M Buy
47,035
+933
+2% +$125K 0.71% 51
2015
Q4
$6.43M Sell
46,102
-55,942
-55% -$7.71M 0.67% 46
2015
Q3
$14.3M Sell
102,044
-13,056
-11% -$1.96M 1.51% 7
2015
Q2
$18.9M Buy
115,100
+3,760
+3% +$601K 1.77% 3
2015
Q1
$17.2M Buy
111,340
+12,394
+13% +$1.76M 1.6% 5
2014
Q4
$12.4M Sell
98,946
-20,877
-17% -$2.58M 1.22% 16
2014
Q3
$14.3M Sell
119,823
-42,121
-26% -$4.83M 1.29% 8
2014
Q2
$17.4M Sell
161,944
-242
-0.1% -$24.9K 1.48% 9
2014
Q1
$16.1M Buy
162,186
+3,877
+2% +$351K 1.43% 9
2013
Q4
$14.6M Buy
158,309
+68,753
+77% +$6.11M 1.31% 10
2013
Q3
$7.49M Buy
89,556
+7,091
+9% +$608K 0.69% 36
2013
Q2
$6.75M Buy
+82,465
New +$6.17M 0.63% 45

Other funds holding ELV

Leuthold Group's ELV Position: Q1 2026 in Review

Leuthold Group sold out of Elevance Health (ELV) in Q1 2026, closing a stake of 22,531 shares — an estimated $7.9M sold.

Leuthold Group first reported a position in ELV in Q2 2013 and held it in 47 quarters. The position peaked at $18.9M in Q2 2015. 1,464 funds tracked by Wall St. Rank hold ELV as of Q1 2026.

  • Leuthold Group reported no remaining Elevance Health position as of Q1 2026 after selling out during the quarter.
  • Leuthold Group sold 22,531 Elevance Health shares in Q1 2026, an estimated $7.9M.
  • Leuthold Group first reported a position in Elevance Health in Q2 2013 and held it in 47 quarters.
  • Leuthold Group's Elevance Health position peaked at $18.9M in Q2 2015.
  • 1,464 funds tracked by Wall St. Rank held Elevance Health as of Q1 2026.

Based on Leuthold Group's 13F filing for Q1 2026, filed 6 May 2026.